Prognose

Analytikernes gennemsnitlige kursmål er 3,47 € (+75,25 %). Medianen er 3,47 € (+75,25 %).

Køb	2
Behold	0
Sælg	0

Nyheder Til nyhedsfeedet

Grace Therapeutics secures $10 million through private placement

Grace Therapeutics announced the closing of a private placement to issue 4,761,904 common shares at $2.10 each, expected to raise about $10 million before costs. The company intends to use the proceeds to fund manufacturing and regulatory work for GTx-104, an injectable nimodipine formulation for aSAH. Grace expects the funds, together with existing cash, to extend its cash runway to the end of 2028; the transaction is expected to close on August 6, 2026. The company has initiated a technology transfer to a second U.S. contract manufacturer and is working to address outstanding CMC and FDA issues from the Complete Response Letter. » Mere på de.investing.com
Grace Therapeutics: cGMP deficiencies at contract manufacturer delay FDA approval of GTx-104

Grace Therapeutics received an FDA Complete Response Letter for GTx-104 that raised no clinical safety or efficacy concerns but cited cGMP compliance issues at a contract manufacturer and requested additional data on extractables/leachables and toxicology assessments. The company is pursuing a two-source strategy and is transferring technology to a second US contract manufacturer while the existing partner addresses the deficiencies and aims for inspection readiness. Grace plans to complete the required nonclinical studies; a further FDA review will be needed once the deficiencies are remedied. GTx-104 is an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage with orphan drug designation; the STRIVE-ON study met its primary endpoint but showed more deaths in the treatment arm versus oral nimodipine, with no link to the therapy. » Mere på de.investing.com
Grace Therapeutics reports Q1 EPS of -$0.06

Grace Therapeutics published results for the quarter ended March 31, 2026: earnings per share were -$0.06, compared with $0.10 a year earlier. For the full year, loss per share was -$0.47, compared with -$0.79 in the prior year. » Mere på finanzen.net

Virksomhedstal

I det seneste kvartal havde Grace Therapeutics Aktie en omsætning på 0 € og et nettoresultat på -13,84 mio. €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	-
Nettoresultat	-13,84 mio.	385,04 %
EBITDA	-13,83 mio.	428,02 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	31,32 mio. €
Antal aktier	16,27 mio.
Højeste/laveste i 52 uger	4,49 € - 1,55 €
Udbytte	Nej
Beta	0,37
P/E (PE Ratio)	-1,77
PEG (PEG Ratio)	0,01
K/I (PB Ratio)	0,80
P/S (PS Ratio)	0,00

Virksomhedsprofil

Grace Therapeutics, Inc. beschäftigt sich mit der Entwicklung und Vermarktung von pharmazeutischen Produkten für seltene und seltene Krankheiten in Kanada. Der führende Produktkandidat des Unternehmens ist GTX-104, eine intravenöse Infusion zur Behandlung von Subarachnoidalblutungen. Außerdem entwickelt es GTX-102, ein orales Betamethason-Spray für die Schleimhaut zur Behandlung der Ataxie-Telangiektasie, und GTX-101, ein topisches, bioadhäsives, filmbildendes Bupivacain-Spray zur Behandlung der postherpetischen Neuralgie. Das Unternehmen war früher als Acasti Pharma Inc. bekannt und änderte im Oktober 2024 seinen Namen in Grace Therapeutics, Inc. um. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Princeton, New Jersey.